About

Cleerly Health focuses on improving the diagnosis and treatment of heart disease through a digital healthcare platform that utilizes artificial intelligence. The platform analyzes coronary computed tomography angiography (CCTA) imaging to detect atherosclerosis, which is the buildup of plaque in the arteries, at an earlier stage. By transforming complex imaging data into clear insights, Cleerly enables healthcare providers to create personalized treatment plans for their patients. This approach allows for a more detailed evaluation of heart disease compared to traditional methods, helping clinicians assess a patient's risk of heart attack more accurately. Cleerly's primary clients are healthcare providers who benefit from enhanced clinical and financial outcomes by using the platform. The company's goal is to improve heart health management and patient outcomes while providing valuable tools for healthcare providers.

Simplify's Take

What believers are saying

• Cleerly's AI-driven platform can significantly improve clinical outcomes by enabling early and accurate diagnosis of heart disease.
• The company's products have demonstrated strong clinical utility, leading to significant changes in clinical decision-making and patient management.
• Cleerly's partnerships and recognitions, such as the Best Use of AI in Health Tech award, highlight its growing influence and credibility in the healthcare sector.

What critics are saying

• The reliance on AI and machine vision technology may face resistance from traditional healthcare providers who are slow to adopt new technologies.
• The competitive landscape in digital healthcare and AI-driven diagnostics is rapidly evolving, posing a threat to Cleerly's market position.

What makes Cleerly unique

• Cleerly Health leverages AI to analyze coronary computed tomography angiography (CCTA) imaging, providing a more precise evaluation of heart disease compared to traditional methods.
• The company's focus on transforming complex imaging data into actionable insights for personalized treatment plans sets it apart from competitors.
• Cleerly's recent FDA Breakthrough Device Designation for its CAD Staging System underscores its innovative approach and potential for significant impact in cardiovascular care.

Help us improve and share your feedback! Did you find this helpful?

YesNo